RSPO3 expands intestinal stem cell and niche compartments and drives tumorigenesis

Conclusions We provide in vivo evidence that RSPO3 stimulates the crypt stem cell and niche compartments and drives rapid intestinal tumorigenesis. This establishes RSPO3 as a potent driver of intestinal cancer and proposes RSPO3 as a candidate target for therapy in patients with colorectal cancer harbouring RSPO3 fusions.

http://gut.bmj.com/cgi/content/short/66/6/1095?rss=1

Source: Gut - May 12, 2017 Category: Gastroenterology Authors: Hilkens, J., Timmer, N. C., Boer, M., Ikink, G. J., Schewe, M., Sacchetti, A., Koppens, M. A. J., Song, J.-Y., Bakker, E. R. M. Tags: Open access GI cancer Source Type: research